Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-05-26
2010-02-02
Woodward, Cherie M (Department: 1647)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S006120
Reexamination Certificate
active
07655415
ABSTRACT:
This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.
REFERENCES:
patent: 5217899 (1993-06-01), Shapiro et al.
patent: 5348879 (1994-09-01), Shapiro et al.
patent: 5786163 (1998-07-01), Hall
patent: 6288218 (2001-09-01), Levinson
patent: 6323334 (2001-11-01), Kingsbury et al.
patent: 7087396 (2006-08-01), Tominaga et al.
patent: 7432060 (2008-10-01), Lee
patent: 2002/0072674 (2002-06-01), Criton et al.
patent: 2003/0124624 (2003-07-01), Tominaga et al.
patent: 2004/0048286 (2004-03-01), Lee
patent: 2005/0130136 (2005-06-01), Lee
patent: 2005/0203046 (2005-09-01), Schmitz et al.
patent: 2008/0003199 (2008-01-01), Lee
patent: 2009/0192078 (2009-07-01), Lee
patent: 6178687 (1994-06-01), None
patent: 7031479 (1995-02-01), None
patent: WO 98/07754 (1998-02-01), None
patent: WO 98/38311 (1998-09-01), None
patent: WO 99/34217 (1999-07-01), None
patent: WO 00/35473 (2000-06-01), None
patent: WO 00/35951 (2000-06-01), None
patent: WO 00/73498 (2000-12-01), None
patent: WO 01/70817 (2001-09-01), None
patent: WO 02/38794 (2002-05-01), None
Oshikawa et al., Am J Respir Crit Care Med. Apr. 1, 2002;165(7):1005-9.
Blum. Annu Rev Med. 2001;52:15-27, Abstract Only.
Galvani et al., Circulatinon.Apr. 15, 1997;95(8):2053-9, Abstract Only.
Selvais et al., J Card Fail. Sep. 2000;6(3):201-7, Abstract Onl.
Goldstein. Am J Cardiol. Dec. 1981;48(6):1147-54, Abstract Only.
Belch et al., Br Heart J. May 1991;65(5):245-8, Abstract Only.
Vidal et al., Prognostic Value of Cytokines and Neurohormones in Severe Heart Failure, Rev Esp Cardiol 2002; 55(5):481-6.
Nozaki et al., Soluble Tumor Necrosis Factor Receptors are Elevated in Relation to Severity of Congestive Heart Failure, Jpn Circ J 1997; 61:657-64.
Orus et al., Prognostic Value of Serum Cytokines in Patients with Congestive Heart Failure, J Heart Lung Transplant 2000; 19:419-25.
GenBank Submission; NIH/NCBI; Accession No. U04319 (ROD May 24, 1995).
GenBank Submission; NIH/NCBI; Accession No. U04317 (ROD May 27, 1994).
GenBank Submission; NIH/NCBI; Accession No. E08652 (PAT Nov. 4, 2005).
GenBank Submission; NIH/NCBI; Accession No. AL117622 (PRI Feb. 18, 2000).
GenBank Submission; NIH/NCBI; Accession No. AB022176 (PRI Sep. 15, 2007).
GenBank Submission; NIH/NCBI; Accession No. AB024518 (PRI Mar. 10, 1999).
GenBank Submission; NIH/NCBI; Accession No. X60184 (ROD Nov. 14, 2006).
GenBank Submission; NIH/NCBI; Accession No. E07714 (PAT Nov. 4, 2005).
GenBank Submission; NIH/NCBI; Accession No. E07716 (PAT Nov. 4, 2005).
GenBank Submission; NIH/NCBI; Accession No. D12763 (PRI Jan. 23, 2003).
GenBank Submission; NIH/NCBI; Accession No. NP—003847 (PRI Nov. 18, 2007).
GenBank Submission; NIH/NCBI; Accession No. NM—003856. (PRI Nov. 18, 2007).
GenBank Submission; NIH/NCBI; Accession No. NP—057316. (PRI Nov. 18, 2007).
GenBank Submission; NIH/NCBI; Accession No. NM—016232. (PRI Nov. 18, 2007).
GenBank Submission; NIH/NCBI; Accession No. D13695. (ROD Feb. 3, 1999).
GenBank Submission; NIH/NCBI; Accession No. Y07519. (ROD Apr. 18, 2005).
GenBank Submission; NIH/NCBI; Accession No. AAA67172. (ROD May 23, 1995).
GenBank Submission; NIH/NCBI; Accession No. AB012701. (PRI Aug. 12, 2005).
GenBank Submission; NIH/NCBI; Accession No. AB029084. (PRI Oct. 31, 1999).
GenBank Submission; NIH/NCBI; Accession No. D12764. (PRI May 29, 2002).
GenBank Submission; NIH/NCBI; Accession No. NM—013037. (ROD Nov. 17, 2006).
GenBank Submission; NIH/NCBI; Accession No. AC007248. (PRI Apr. 21, 2005).
Information Hyperlinked Over Proteins—Symbol IL1RL1.
NCBI BLASTN 2.2.2 [Dec. 14, 2001], Blast Results (21 pages).
NCBI BLASTN 2.2.2 [Dec. 14, 2001], Blast Results (15 pages).
NCBI BLASTN 2.0.14 [Jun. 29, 2000], Blast Results, Query 2065 letters, (5 pages) printed Aug. 23, 2000.
NCBI BLASTN 2.0.14 [Jun. 29, 2000, Blast Results, 2586 letters, (5 pages) printed Aug. 23, 2000.
NCBI BLASTN 2.0.14 [Jun. 29, 2000], Blast Results, 2065 letters, (5 pages) printed Aug. 23, 2000.
NCBI BLASTN 2.0.14 [Jun. 29, 2000], Blast Results, 2586 letters, (5 pages) printed Aug. 23, 2000.
Monoclonal Antibody: Anti-Human ST2; Medical & Biological Laboratories Co., Ltd., Aug. 23, 2000 (2 pages).
Millenium Pharmaceuticals, Inc. Millenium Pharmaceuticals Identifies a Key mediator of Allergic Immune Response. Press Release Oct. 4, 1999, 2 pages.
Albert et al., Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation. Jun. 4, 2002;105(22):2595-9.
Auer et al., C-reactive protein and coronary artery disease. Jpn Heart J. Nov. 2002;43(6):607-19.
Aukrust et al., Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. Feb. 1, 1999;83(3):376-82.
Baumgarten et al., Cytokines as emerging targets in the treatment of heart failure. Trends Cardiovasc Med. Jul. 2000;10(5):216-23.
Brown, Techniques for mechanical stimulation of cells in vitro: a review. J Biomech. Jan. 2000;33(1):3-14. Review.
Carter RW, et al. Regulation of ST2L expression on T helper (Th) type 2 cells. Eur J lmmunol. Oct. 2001;31(10):2979-85 Abstract Only.
Chan WL, et al. Human IL-18 receptor and ST2L are stable and selective markers for the respective type 1 and type 2 circulating lymphocytes. J Immunol Aug. 1, 2001;167(3):1238-44 Abstract Only.
Cheng et al., Mechanical strain tightly controls fibroblast growth factor-2 release from cultured human vascular smooth muscle cells. Circ Res. Jan. 1997;80(1):28-36.
Coyle et al., Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med. Oct. 4, 1999;190(7):895-902.
De Keulenaer et al., Identification of IEX-1 as a biomechanically controlled nuclear factor-kappaB target gene that inhibits cardiomyocyte hypertrophy. Circ Res. Apr. 5, 2002;90(6):690-6.
Feldman et al., C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. J Acquir Immune Defic Syndr. Feb. 1, 2003;32(2):210-4. Abstract Only.
Feng et al., Transcriptional profile of mechanically induced genes in human vascular smooth muscle cells. Circ Res. Dec. 3-17, 1999;85(12):1118-23.
Forssmann et al., The heart is the center of a new endocrine, paracrine, and neuroendocrine system. Arch Histol Cytol. 1989;52 Suppl:293-315. Review. Abstract Only.
Gutstein et al., Role of inositol 1,4,5-trisphosphate receptors in regulating apoptotic signaling and heart failure. Heart Vessels. 1997;Suppl 12:53-7.
Gwechenberger et al., Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation. Feb. 2, 1999;99(4):546-51.
Hanyu T, et al. Urinary Thrombomodulin in Patients with Rheumatoid Arthritis: Relationship to Disease Subset. 1999; 18:385-9.
Heeschen et al., Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. Capture Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina Refractory to standard treatment trial. J Am Coll Cardiol. May 2000;35(6):1535-42. Abstract Only.
Hirota et al., Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell. Apr. 16, 1999;97(2):189-98.
Iwahana et al., Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem. Sep. 1999;264(2):397-406.
Izakov et al., Cooperative effects due to calcium binding by troponin and their consequences for contraction and relaxation of cardiac muscle under various conditions of mechanical loading. Circ Res. Nov. 1991;69(5):1171-84.
Januzzi et al., Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in pa
The Brigham and Women's Hospital, Inc.
Wolf Greenfield & Sacks P.C.
Woodward Cherie M
LandOfFree
IL1RL-1 as a cardiovascular disease marker and therapeutic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IL1RL-1 as a cardiovascular disease marker and therapeutic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IL1RL-1 as a cardiovascular disease marker and therapeutic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4221291